Pharmaceuticals, Biotechnology and Life Sciences
EUCRISA is the first and only 100% steroid-free, topical prescription medication approved for patients as young as 3 months of…
Pfizer and BioNTech on Tuesday said they have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together on a potential mRNA-based coronavirus vaccine for preventing COVID-19 infection.
BioNTech SE said Monday its development a potential vaccine to induce immunity and prevent COVID-19 infection in response to the growing global health threat posed by the disease has seen rapid progress. BioNTech’s product candidate, BNT162, is a potential first-in-class mRNA vaccine in the worldwide effort against COVID-19.
How do pharmaceutical companies prophet from COVID-19? Do they make the profit?
Chairman and CEO Albert Bourla Calls on Biopharma Industry to Collaborate on Combatting the Global Pandemic NEW YORK–(BUSINESS WIRE)–Pfizer today…
Pfizer has presented positive phase 3 data at the 28th Congress of the European Academy of Dermatology and Venereology for abrocitinib in moderate to severe atopic dermatitis, in which abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study.
Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.
Pfizer’s study of investigational Oral JAK1 candidate in Abrocitinibfor Severe Atopic Dermatitis hits targets achieves all co-primary and key secondary endpoints, as safety results show both doses of abrocitinib consistent with prior clinical trial experiences.
Presentations of interest include a late-breaking abstract on expanded Phase 3 data in BRAF-mutant metastatic colorectal cancer NEW YORK–(BUSINESS WIRE)–Pfizer…
Technavio’s market research reports examine the competitive landscape and provide detailed insights into the market scenario over the next five years.